BioCentury | Feb 4, 2013
Emerging Company Profile

Incanthera: Using, not targeting, MMP

...the clinic have been abandoned due to lack of specificity and resulting musculoskeletal side effects. Incanthera...
...selective for MMP14 and MMP15, and these are really only present at solid tumor sites," Incanthera...
...in preclinical testing to treat cancer. Kadmon licensed the compound from Dyax Corp. last year. Incanthera...
BioCentury | Jan 23, 2012
Financial News

Incanthera completes venture financing

Incanthera Ltd. , Merseyside, U.K. Business: Cancer Date completed: 1/18/12 Type: Venture financing Raised: £375,000 ($573,938) Investor: North West Fund for Biomedical WIR Staff cancer...
BioCentury | Jan 20, 2012
Financial News

Incanthera debuts

...Newco Incanthera Ltd. (Merseyside, U.K.) raised L375,000 ($574,000) in a seed round led by the North West...
Items per page:
1 - 3 of 3
BioCentury | Feb 4, 2013
Emerging Company Profile

Incanthera: Using, not targeting, MMP

...the clinic have been abandoned due to lack of specificity and resulting musculoskeletal side effects. Incanthera...
...selective for MMP14 and MMP15, and these are really only present at solid tumor sites," Incanthera...
...in preclinical testing to treat cancer. Kadmon licensed the compound from Dyax Corp. last year. Incanthera...
BioCentury | Jan 23, 2012
Financial News

Incanthera completes venture financing

Incanthera Ltd. , Merseyside, U.K. Business: Cancer Date completed: 1/18/12 Type: Venture financing Raised: £375,000 ($573,938) Investor: North West Fund for Biomedical WIR Staff cancer...
BioCentury | Jan 20, 2012
Financial News

Incanthera debuts

...Newco Incanthera Ltd. (Merseyside, U.K.) raised L375,000 ($574,000) in a seed round led by the North West...
Items per page:
1 - 3 of 3